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Abstract
Background: Total tau (T-tau) and b-amyloid(1-42)
(Ab1-42) levels in cerebrospinal fluid (CSF) can differ-
entiate Alzheimer’s disease (AD) from normal aging
or depressive pseudo-dementia. Differential diagnosis
from dementia with Lewy bodies (DLB) in clinical set-
tings is difficult.
Methods: The analytical performance of the INNO-
TEST PHOSPHO-TAU(181P) assay was validated in
terms of selectivity, sensitivity, specificity, precision,
robustness, and stability. Clinical utility of the assay
alone, or combined with T-tau and Ab1-42, for discrim-
ination of AD (ns94) from patients suffering from
DLB (ns60) or from age-matched control subjects
(CS) (ns60) was assessed in a multicenter study.
Results: CSF concentrations of tau phosphorylated at
threonine 181 (P-tau181P) in AD was significantly high-
er than in DLB and CS. Discriminant analysis, a clas-
sification tree, and logistic regression showed that
P-tau181P was the most statistically significant single
variable of the three biomarkers for discrimination
between AD and DLB.
Conclusions: P-tau181P quantification is a robust and
reliable assay that may be useful in discriminating AD
from DLB.
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Introduction
Alzheimer’s disease (AD) can be considered the most
important neurodegenerative brain disease because
of its frequent occurrence and devastating conse-
quences, affecting up to 10% of the population older
than 65 years. Its impact is increasing in parallel with
the general worldwide aging of the population. His-
tologically, brains of AD patients are characterized by
the presence of neurofibrillary tangles (NFT), senile
plaques, and synapse loss (1). The major component
of the NFT structures is hyperphosphorylated tau pro-
tein. Tau protein is a normal brain phosphoprotein
that binds to microtubules in neuronal axons, thereby
promoting neural assembly and stability. When
hyperphosphorylated, tau loses its stabilizing func-
tion, resulting in axon instability and reduced intra-
cellular transport. More than 70 potential phosphory-
lation sites have been identified in the tau molecule
(2). Tau and phospho-tau are closely associated with
the pathology of several age-related neurodegenera-
tive disorders, such as AD, frontotemporal lobe
dementia (FTD), and dementia with Lewy bodies
(DLB). More reliable diagnostic procedures are requir-
ed, since AD is only correctly diagnosed in clinical set-
tings in 65%–90% of cases (3). The higher percentage
is especially associated with academic settings with
clinical follow-up, while the lower figure more likely
occurs in non-academic settings and at first clinical
work-up. Consensus criteria for AD biomarkers have
been published (4).
Earlier studies indicated that tau phosphorylated at
threonine 181(P-tau181P) in cerebrospinal fluid (CSF)
might be used to discriminate AD from DLB (5). Since
distinction of AD from DLB is difficult in clinical set-
tings, but important for patient management, as the
treatment strategies are different, P-tau181P determi-
nation may prove to be of clinical value. In addition,
combined measurement of b-amyloid(1-42) (Ab1-42) and
P-tau181P levels has been shown to differentiate AD
from FTD (6).
We describe the performance characteristics of the
INNOTEST PHOSPHO-TAU(181P) assay and an evalu-
ation of its clinical utility, alone or combined with total
tau (T-tau) and Ab1-42 for the discrimination of AD
from DLB and control subjects (CS).
Materials and methods
Assays
The INNOTEST PHOSPHO-TAU(181P) assay is a solid-phase
enzyme immunoassay in which P-tau protein is captured by
monoclonal antibody (mAb) HT7 (Innogenetics, Gent, Bel-
gium). A sample of 75 mL of undiluted CSF is added and
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incubated overnight at 2–88C with 25 mL of the biotinylated
anti-P-tau181P mAb AT270 (Innogenetics). Any antigen-anti-
body complex formed is then detected by peroxidase-
labeled streptavidin (SV-PO). Two wash steps are included
in the test instructions: one after incubation of the antigen
and biotinylated detector antibody, and the other after SV-
PO. No difference was observed between a manual wash
procedure or an automated wash procedure on a Columbus
instrument (data not shown). The assay contains a sample
addition monitoring system to confirm the addition of CSF
or SV-PO. A phosphorylated peptide, containing both the
epitope of HT7 (epitope P159PGQK163, numbered according
to the longest tau isoform) (7) and AT270 (epitope
P176PAPKTP182), was used for calibration (peptide sequence,
acetyl-P154RGAAPPGQKGQANATRIPAKTPPAPKTPPSSGE187;
molecular weight, 3455 Da; obtained from Neosystems,
Strasbourg, France). The calibrator peptide should be con-
sidered as a reference standard. Its structure and size differ
from the size of the native P-tau protein. The assay format
quantifies all tau isoforms phosphorylated at threonine 181.
Full details of the assays used in the present study have been
described previously (8–10).
Production process
Plate coating The process of mAb coating of immuno-
plates (Nunc Maxisorps, San Diego, CA, USA) was fully
validated. The homogeneity of the mAb coating was verified
for each production run by performing an assay with 125
pg/mL of the calibrator peptide. For this purpose, immuno-
plates were assembled containing 8-well strips obtained
from plates selected over the whole production run. Two
combined plates were used for testing. Half of the plate
(either the upper or lower part) was filled with 125 pg/mL of
the calibrator (positive sample) or the blank (negative sam-
ple). The percentage coefficient of variation (%CV) for the 96
positive samples was calculated. The effect of the blocking
and fixation stabilization process on P-tau181P concentrations
measured in CSF was verified for 38 CSF samples (concen-
tration range 3.5–207.4 pg/mL; calculated on fresh plates) by
comparison of results obtained on fresh and stabilized
immunoplates, as assessed by a paired two-tailed t-test on
log-transformed values.
Stability The stability of the whole kit was evaluated on
kits from two production runs. All components of the kit
were stored at 2–88C for more than 24 months. Calibrator
peptides were stored at 2–88C or y208C. At each time point,
assays were performed according to the test instructions.
Three control samples (run validation samples) were pre-
pared by addition of calibrator peptides to artificial CSF
(ACSF) (composition NaCl, 138 mM; KCl, 2.8 mM;
CaCl2Ø2H2O, 1.05 mM; MgCl2Ø6H2O, 1.15 mM; NaH2PO4ØH2O,
1.25 mM; glucose, 0.06% w/w; and human serum albumin,
0.16% w/w).
The effect of freezing (up to ten times) on the prepared
calibrator concentration range was also evaluated. At each
time point, three aliquots of each calibrator concentration
were taken and analyzed on two different mAb-coated
plates. Each vial was stored for at least 1 day after each freez-
ing cycle at y208C. All samples were analyzed in the same
experiment.
Analytical performance
Curve fitting Experiments were performed to select the
most appropriate mathematical model for curve fitting, as
well as the number and concentration of dilutions. A lack-of-
fit test determined whether the predicted sigmoidal calibra-
tion curve adequately described the data obtained.
Evaluation was performed based on model fit (R2 values),
residual analysis, and analysis of the variability on inverse
prediction (e.g., estimating concentrations for unknown
samples).
Selectivity and specificity Selectivity (ability of the assay
to measure and differentiate P-tau181P in the presence of
matrix components that may be expected to be present) and
specificity (detection of P-tau181P as opposed to other P-tau
proteins) were evaluated using synthetic biotinylated pep-
tides (sequence Q165ANATRIPAKTPPAPKTPPSSGEPPKS191)
either phosphorylated at Thr181 or non-phosphorylated. For
this purpose, SV-coated immunoplates were first incubated
for 1 h with biotinylated peptides. After a wash step, mAbs
were incubated overnight at 2–88C. Detection of the bound
mAbs was achieved using peroxidase-labeled goat anti-
mouse antibodies (Jackson Immunoresearch Laboratories,
Lucron Bioproducts; De Pinte, Belgium).
Analytical sensitivity Blank samples (bl) (;sample diluent)
were used to calculate the limit of detection (LOD; meanblq2
SDbl) and lower limit of quantitation (LLOQ; meanblq10
SDbl). The upper limit of quantitation (ULOQ) was deter-
mined from linearity and accuracy results.
Accuracy Using data from the precision experiments, the
percentage bias (known value–predicted value/known val-
ue=100%) was calculated. However, in principle, accuracy
(closeness of test results obtained by the method to the true
concentration of the analyte) was difficult to define in this
case, since no reference material (gold standard) is currently
available.
Repeatability and reproducibility Intermediate precision
(closeness of individual measurements of an analyte when
the procedure is applied repeatedly) was evaluated by the
analysis of 12 samples (including six points for calibration
and two blanks) for eight replicates on three coated ELISA
plates from five different production runs. For each plate and
sample, the average, SD, CV, and bias were calculated using
the calibrator curve provided in the kit.
Repeatability and reproducibility were tested according to
ISO 5725-2 guidelines (11). Control samples were analyzed
by three different operators in quadruplicate, using three dif-
ferent vials of calibrators on ELISA plates from the same
production run (repeatability), or by one operator in quad-
ruplicate using the same calibrators on plates from three
different production runs (reproducibility). The method per-
formance chart presents inaccuracy (percentage bias) plot-
ted against the imprecision (CV).
Linearity Assay linearity (ability of the method to elicit test
results that are directly proportional to the analyte concen-
tration) was evaluated by combining samples with high or
low concentrations of P-tau181P in different volume ratios
(1:0, 0.75:0.25, 0.5:0.5, 0.25:0.75 and 0:1). Results calculated
for the mixed samples were plotted against predicted con-
centrations obtained in undiluted CSF.
Test robustness The robustness (capacity of the assay to
remain unaffected by deliberate variations in method par-
ameters) or effect of variation in test parameters (antigen
and detector-antibody incubation time; SV-PO incubation
time, SV-PO incubation temperature, substrate incubation
time, and substrate incubation temperature) on assay per-
formance was characterized by factorial design of experi-
ments. In a full factorial design, all combinations of
boundary assay parameter settings were tested on ACSF
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Table 1 Assay parameters tested.
Boundary settings
Low Standard High
Antigen incubation time, h 14 16 18
SV-PO incubation time, min 55 60 65
SV-PO incubation temperature, 8C 18 24 30
Substrate incubation time, mina 27 30 33
Substrate incubation temperature, 8C 18 24 30
a For substrate incubation, only the combined low and high settings were included in combinations with settings of the other
factors.
samples, spiked with different concentrations of P-tau181P-
peptide (Table 1). Each sample was tested in quadruplicate.
CSF sample preparation To assess the effect of centrifu-
gation, CSF samples (ns15, concentration range 20–160
pg/mL P-tau181P) were either aliquoted immediately after col-
lection and stored at y808C, or centrifuged at 2000 g for
10 min at 48C and subsequently frozen aty808C. A Wilcoxon
matched-pairs test was used to compare both methods.
To assess the effect of storage conditions, CSF samples
(ns11) were aliquoted and stored immediately at y808C, or
stored for 4, 24, or 72 h at 48C or at room temperature before
freezing at y808C. Repeated-measures ANOVA was used to
evaluate the effects of temperature storage conditions.
To evaluate the impact of freezing, CSF samples (ns8)
stored at y808C were thawed and refrozen several times.
Each CSF sample was stored at y808C for at least 1 night.
The effect of additional freezing of CSF was evaluated by
repeated-measures ANOVA.
Clinical utility using stored patient samples
Samples The multicenter study used previously stored
CSF samples available for research purposes from five lab-
oratories. No follow-up samples were included in the study.
Patients suffering from relevant concomitant diseases, such
as brain tumors or metastases, CSF infection or stroke, were
excluded. The AD group (ns94) consisted of randomly
selected patients diagnosed with probable AD according to
DSM-IV criteria and criteria established by the work group of
the National Institute of Neurological and Communicative
Disorders and Stroke/Alzheimer’s Disease and Related Dis-
orders Association (NINCDS-ADRDA) (12). DLB patients
(ns60) were randomly selected and diagnosed according to
the criteria of McKeith et al. (13). Mini-mental state exami-
nation (MMSE) (14) scores were documented for most
patients and for some of the CS. Clinical diagnosis preceded
or coincided with CSF collection. CS (ns60) were defined as
either (i) apparently healthy (ns37) or (ii) subjects without
systemic inflammatory or central nervous system disorders,
aged over 55 years, who had undergone lumbar puncture
and CSF collection for diagnosis of mechanical problems
(ns6; 2 nucleopathies, 1 headache in epilepsy, 1 disk her-
niation, 1 cervical lumbar arthrosis, 1 minor head trauma) or
(iii) depression (ns17). Only CSF samples collected in the
2 years preceding the study start, stored in polypropylene
tubes, and kept (pending biochemical analysis) frozen at
y208C or lower were included. The number of freeze/thaw
cycles was recorded.
All clinical samples were tested in duplicate at the respec-
tive centers (multicenter collection and testing). Operators
were blinded to the expected test outcome in terms of clin-
ical diagnosis. Concentrations of P-tau181P, T-tau, and Ab1-42
were required for all samples. When historical results of
INNOTEST hTAU Ag and INNOTEST b-AMYLOID(1-42)
assays were available, the investigator was free to decide
whether or not to repeat these analyses. As such, results for
T-tau and Ab1-42 need to be interpreted with some caution,
as they were partly based on historical results not obtained
in the standardized protocol setting.
The study presented no risk(s) or harm to the subjects.
Previously stored samples available for research purposes
were used for this study. Ethics Committee approval to con-
duct the study was not required for three centers, was
obtained in one center for research purposes, and was given
for the fifth center. Subject confidentiality was maintained at
all times, within the legal context of the country, by removal
of all direct subject identifiers from patient samples and clin-
ical documentation submitted for this study. Anonymity was
also assured in any report or publication.
Statistics
Several statistical techniques wreceiver operating character-
istic curve (ROC) analysis, discriminant analysis, classifica-
tion tree, and logistic regressionx were used in an attempt to
optimally classify AD, DLB, and CS in the correct group
based on biomarker information. Transformed variables
were employed if this resulted in increased discriminative
power. A Wilcoxon rank sum test was used to compare
group differences. Spearman’s correlation was used to eval-
uate correlation of P-tau181P and age or MMSE. The data for
each assay were analyzed using sigmoidal curve fitting with
the GraphPad Prism program (Version 4.01; GraphPad Soft-
ware, San Diego, CA, USA).
Results
Production process
The homogeneity of the coating process was ana-
lyzed by performing an assay with 125 pg/mL of the
calibrator peptide on immunoplates obtained from
ten different production runs. The median CV (p10–
p90) for the positive sample was 3.8% (2.6%–5.8%).
The process of blocking and fixation of mAbs on the
plates did not affect the P-tau181P concentration in
CSF, as verified for 38 CSF samples (paired t-test on
log-transformed values, ps0.145).
The stability of the total kit after a storage period of
more than 2 years for different production runs was
fully documented. Regression analysis on log-trans-
formed values of concentrations for control samples
did not show a statistically significant difference in P-
tau181P concentrations as a function of storage time
(kit stability). In addition, the P-tau181P concentration
in CSF (ns2) stored at y808C did not change over a
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Figure 1 Storage and freezing. Effect of storage conditions
of CSF samples on P-tau181P concentrations. C, stored imme-
diately at y808C; RT, room temperature, defined as 20–258C.
Figure 2 Assay linearity: combinations of CSF samples with
high and low concentrations of P-tau181P. A, B, C are different
CSF combinations.
Table 2 Repeatability (r) and reproducibility (R).
Sample Intra-lot CV, % Inter-lot CV, %
r R r R
Low reactivity 3.1 7.1 2.7 8.0
Medium reactivity 2.8 6.5 1.4 5.1
High reactivity 2.5 8.4 2.5 3.2
period of more than 2 years, suggesting the possibil-
ity of storing CSF samples for extended periods. The
CV for these samples amounted to 9.6% and 8.1%
(ns19 test runs) (sample stability).
Concentrated stock solutions of calibrator peptides
were stable for more than 2 years when stored at
2–88C (as compared to storage at y208C). A Wilcoxon
matched-pair test revealed no statistical differences
between concentrations determined with the frozen
or unfrozen calibrator peptides for three control sam-
ples. Working solutions of calibrators were repeatedly
frozen and thawed (up to 10 times). Regression anal-
ysis on log-converted concentrations revealed a non-
significant decrease for concentrations of 15.6 pg/mL
(ps0.129), 62.5 pg/mL (ps0.972) and 125 pg/mL
(ps0.069), and a significant decrease for 31.25 pg/mL
(ps0.003). A Kruskal-Wallis test revealed that the sig-
nificant difference for the 31.25 pg/mL was solely due
to the values obtained after ten freeze/thaw cycles. It
is essential to limit the number of freezing steps for
the calibrators.
Analytical performance
Curve fitting Selection of the model for curve fitting
was based on experiments with more than ten cali-
brators over a wide concentration range. The sigmoi-
dal (four-parameter logistic) curves selected provided
excellent fits (R2s0.99 or higher) and residuals. There
was an acceptable linear relation between the con-
centrations predicted from the calibrator curve or
from an independent set of samples and the known
concentrations over the complete calibration range of
15.6–500 pg/mL.
Analytical selectivity and specificity The AT270
mAb recognized tau phosphorylated at threonine 181.
No reactivity was obtained using non-phosphorylated
peptides or tau phosphorylated at other sites (data
not shown). No cross-reactivity with recombinant tau
was obtained in quantified CSF in concentration rang-
es corresponding to healthy and diseased subjects.
CSF handling procedures The inclusion of several
freeze/thaw cycles (ns5), as well as evaluation of the
need for a centrifugation step before storage of the
CSF, did not result in a significant effect on P-tau181P
concentrations (data not shown). The effect of storage
of CSF for a limited period is shown in Figure 1. No
significant difference in P-tau181P concentration was
noted between CSF samples stored for 3 days at room
temperature and samples frozen immediately after
collection (ps0.913).
Linearity Three different pairs of CSF samples, con-
taining high and low concentrations of P-tau181P, were
combined in different ratios. When the calculated con-
centrations were plotted against predicted concentra-
tions, no deviation from the bisector could be
observed, indicating the absence of matrix effects
under the experimental conditions (Figure 2).
Repeatability and reproducibility The inter- and
intra-lot variability was tested for low-, medium-, and
high-reacting control samples. Results are shown in
Table 2. All CV values (within or between production
runs) were lower than 8.5%.
Assay sensitivity and precision Twelve samples
were tested using eight replicates on three plates
from five different production runs. The LOD deter-
mined was 10–15 pg/mL and LLOQ was 22–28 pg/mL.
Figure 3A shows the precision profile of the pooled
data for all the plates. Figure 3B shows the method
performance chart (bias as a function of CV). The CV
was less than 10% for levels between 15.6 and 300
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Figure 3 (A) Calibrator curve and precision profiles for cal-
ibrators of the INNOTEST PHOSPHO-TAU(181P) assay. Pre-
cision profile expressed as percentage CV (o), with
calibration curve plotted on the same graph (●) as well as
the concentration range expressed as 5th (p5) and 95th per-
centiles (p95) for CSF samples included in the clinical study.
(B) Method performance chart, established with calibrator
peptides, for the INNOTEST PHOSPHO-TAU(181P) assay. Val-
ues represent concentrations of calibrator peptides.
Figure 4 Summary of patient samples. Numbers in parentheses are historical results. AD, Alzheimer’s disease; DLB, dementia
with Lewy bodies; CS, control subjects.
pg/mL. The higher calibrator concentrations showed
lower precision. Bias was below 5% for concentra-
tions between 15.6 and 300 pg/mL. Bias may exceed
10% for the highest concentrations. Good to excellent
performance was obtained between LLOQ and ULOQ
or higher. The validated range was estimated to be
between 25 and 250 pg/mL.
Test robustness Different combinations of bound-
ary assay parameters resulted in clear differences in
OD output for control samples. However, at the level
of P-tau181P concentrations, differences in boundary
assay parameters (see also Table 1) remained within
the range of random test variation. It was also noted
that for the two samples in the linear test range, the
CV was less than 10% in all assay parameter combi-
nations tested (data not shown).
Clinical utility
Sample disposition The study was conducted
between March and May 2002. Initially, 223 CSF sam-
ples were included in the study (Figure 4). Ten sam-
ples were excluded from statistical analysis since they
did not meet the inclusion criteria. Statistical analysis
revealed a center effect, with P-tau181P values gener-
ally lower for center 04. Criteria for pooled analysis
were defined prospectively in the protocol. As a
result, P-tau181P data from center 04 were omitted in
the calculations for cutoff value, sensitivity, and
specificity.
Diagnostic characteristics Demographic data and
CSF concentrations of P-tau181P, Ab1-42, and T-tau in
the three diagnostic groups are described in Table 3.
Independent of the center effect mentioned, signifi-
cantly higher P-tau181P levels were observed for AD
compared to DLB (p-0.001) and CS (p-0.001). No
significant difference was observed between the DLB
and CS groups (p)0.05). For Ab1-42 (data from five
centers), significantly lower levels were observed for
AD compared to CS (p-0.001) and for DLB compared
to CS (p-0.001). No significant difference was
observed between DLB and AD groups (ps0.522). For
T-tau (data from five centers), significantly higher lev-
els were observed for AD compared to CS (p-0.001)
and DLB (p-0.001), while no differences were seen
between CS and DLB (ps0.077).
In the present study, P-tau181P concentrations did
not differ as a function of gender. No significant cor-
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Table 3 Demographic and biomarker data for patients enrolled in the study.
Patient data AD DLB CS
Number of patients (M/F) 94 (55/39) 60 (21/39) 59 (35/24)
Age, years 67.5 (60.3, 77.0) 74.0 (71.0, 78.0) (1) 64.0 (58.8, 73.0)
MMSE 21.0 (15.0, 24.0) (2) 20.5 (17.0, 25.0) (2) 29.0 (28.3, 29.8) (49)
ApoE
Missing data 27 22 32
No E4 26 20 18
One E4 32 18 9
Two E4 9 0 0
Biomarker levels, pg/mL
P-Tau181P 83.5 (54.3, 106.4) 47.6 (34.0, 58.0) 42.4 (34.3, 53.5) (1)
T-tau 610.0 (416.1, 868.5) (1) 271.5 (200.6, 356.7) 175.5 (127.7, 289.6)
Ab1-42 377.5 (285.0, 494.8) 433.9 (337.7, 532.3) 702.9 (550.9, 830.0)
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; CS, control subjects. Results are expressed as median (25th, 75th
percentiles). The number of missing values is shown in italics.
Table 4 Comparison of the AUC for P-tau181P, Ab1-42, and T-tau for discrimination of AD from CS or DLB.
AD vs. CS AD vs. DLB
P-tau181P 0.867"0.031 (76/53; p-0.001) 0.821"0.036 (76/51; ps0.780)
Ab1—42 0.881"0.033 (77/54; ps0.010) 0.588"0.052 (77/52; p-0.001)
T-tau 0.908"0.026 (77/54; ps0.021) 0.798"0.038 (77/52; ps0.512)
Model: Ab42s240q1.18=tau (14) 0.960"0.017 0.815"0.037
Results are expressed as AUC"SE (number of patients in the analysis, AD/CS or AD/DLB), with significance as compared to
the model described in reference (14). Data were obtained from four centers; only results for which all parameters were
available were included in the study. Significance values between parameters are further explained in the Results section.
Table 5 Sensitivity, specificity, and overall accuracy for discrimination of AD from CS.
Sensitivity, % Specificity, % Overall accuracy, %
T-tau and Ab1-42
Discrimination line (14) 92.3 83.1 88.7
Discriminant analysis 88 93 90
Discriminant analysis (log transformed values) 89 93 91
Classification tree 94.6 86.4 91.4
Logistic regression 91.3 89.8 90.7
P-tau181P and Ab1-42
Discriminant analysis 84 85 84
Discriminant analysis (log transformed values) 85 86 85
relation between P-tau181P levels and age was found
in CS (ps0.091), AD (ps0.852) or DLB (ps0.125). In
the AD and DLB groups, there was no correlation
between apolipoprotein E (apoE) genotype and P-
tau181P levels (p)0.05). Furthermore, no significant
correlation of P-tau181P was found with MMSE in AD
(rs0.165; ps0.160) and DLB patients (rs0.085;
ps0.551). In addition, no effect of blood-brain barrier
deficits or gradient on P-tau181P concentrations was
found (unpublished observations obtained from one
center).
Classification A ROC curve describes true-positive
vs. false-positive rates of a diagnostic test at different
cutoff values. The area under the curve (AUC) is con-
sidered as a measure of the discriminative power of
the test. Table 4 summarizes ROC curves for the dif-
ferential diagnosis of AD-DLB and AD-CS. For AD vs.
CS or DLB, the AUC obtained for T-tau or Ab1-42 was
not significantly different between analyses with and
without center 04 (data not shown). The AUC for T-
tau was not statistically significantly different from
the AUC for P-tau181P to discriminate AD vs. DLB
(ps0.175), but significantly higher than the AUC for
P-tau181P to discriminate AD vs. CS (ps0.039). The
AUC for Ab1-42 was not significantly different from the
AUC for P-tau181P to discriminate AD vs. CS (ps0.805),
but significantly lower than for P-tau181P to discrimi-
nate AD vs. DLB (p-0.001).
To discriminate between AD and CS, P-tau181P,
T-tau, and Ab1-42 were entered into different algo-
rithms, including a previously published model com-
bining T-tau and Ab1-42 (15). Using discriminant
analysis, a classification tree, or logistic regression, P-
tau181P was removed from this model and diagnostic
question, as it did not significantly contribute to the
discrimination in this model. As a consequence, the
center effect for P-tau181P was not relevant in this con-
text. The resulting sensitivity, specificity, and overall
accuracy of the models are shown in Table 5. To dis-
criminate AD from CS, the AUC is significantly aug-
mented using the previously described discrimination
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Table 6 Sensitivity, specificity, and overall accuracy for discrimination of AD from DLB.
Sensitivity, % Specificity, % Overall accuracy, %
Discriminant analysis (P-tau181P) 74 85 78
Discriminant analysis (log transformed values) 82 81 81
Classification tree (P-tau181P) 80 79 80
line (14) compared to T-tau (ps0.021), P-tau181P
(p-0.001) or Ab1-42 (ps0.010) analyzed individually.
By analogy, P-tau181P, T-tau, and Ab1-42 were
entered into algorithms to discriminate AD from DLB.
The point on the P-tau181P ROC curve at which sensi-
tivity and specificity are maximal for differentiation of
AD from DLB was determined as 61 pg/mL. Using this
cutoff, a sensitivity of 80% and specificity of 79% were
obtained (Table 6).
However, in the discriminant analysis model for AD
vs. DLB, it is important to note that P-tau181P alone is
the most important variable in the discrimination
between AD from DLB. P-tau181P and Ab1-42 remained
in the discriminant analysis log-transform model,
whereas T-tau was rejected. The most important var-
iable in the classification tree was P-tau181P, resulting
in a cutoff value of 61 pg/mL. P-tau181P was also the
most important variable in the logistic regression
model. The cutoff value from the logistic regression
model was calculated as 59.4 pg/mL. The resulting
sensitivity, specificity, and overall accuracy of the dif-
ferent models are shown in Table 6.
Discussion
We describe here the analytical and clinical perform-
ance of the INNOTEST PHOSPHO-TAU(181P) ELISA for
quantification of P-tau181P in CSF. Both phosphorylat-
ed and non-phosphorylated tau isoforms have been
identified in CSF, fetal human brain, and adult human
brain tissue (16, 17). We found that the quantification
of P-tau181P levels in CSF, using a combination of
mAbs AT270 and HT7, was specific; reactivity towards
other phosphorylated epitopes and non-phosphoryl-
ated tau protein was absent, confirming previously
published characterization data (10, 16, 18). Linearity
experiments pointed to a high accuracy level when
using undiluted CSF samples. When reproducibility
and repeatability experiments were performed (with
operators, lot numbers, or test runs as variables), the
CV for samples in the assay range were below 15%.
Notwithstanding the validated robust assay format,
the stability of the kit for at least 13 months (as stated
in the kit insert), the relative stability of P-tau181P in
CSF, and the possibility to freeze/thaw calibrator pep-
tides, it is still important to carry out on-site training
to obtain the best assay performance. This could
avoid center effect(s) as observed in the present
study. The production process resulted in a real-time
stability of at least 13 months. Extension of this shelf
life in the future will be an advantage in clinical trials,
since clinical trials sometimes run for more than
2 years before finalization; kits from a single lot could
be used to analyze all samples in a specific study. In
addition, different CSF handling protocols were eval-
uated. No effect on P-tau181P concentrations was not-
ed after centrifugation or storage for up to 3 days at
258C before freezing at y808C. However, repeated
freezing and thawing of CSF is not recommended,
especially when P-tau181P is to be analyzed in combi-
nation with other biomarkers, such as Ab1-42 (9).
The results of the clinical study extend a previous
report (5) on the value of P-tau181P testing in CSF for
discriminating AD from DLB. An overall accuracy level
of 80% was observed, which may be difficult to
improve on by single-parameter analysis, considering
the level of accuracy of clinical diagnosis compared
with postmortem findings. The present study also
confirmed the reported discrimination line (15) based
on the combination of CSF T-tau and Ab1-42 for dis-
criminating AD from CS. The use of P-tau181P could
not improve this result. However, P-tau181P was
shown to be the most important variable among the
different biomarkers in discriminating between AD
and DLB, although AUC differences for P-tau181P com-
pared to T-tau did not reach statistical significance.
Notably, when P-tau181P was used to classify patients
instead of T-tau, six additional patients were correctly
classified as DLB, whereas Ab1-42 was shown to have
no discriminatory power in distinguishing AD from
DLB. Moreover, using different statistical models
based on the three biomarkers, P-tau181P was consis-
tently identified as the most important marker in the
discrimination of AD from DLB.
In the study of Mollenhauer et al. (19), significantly
different values were obtained for the comparison
between AD and DLB for T-tau and the T-tau/P-tau181P
ratio, but not for Ab1-42, P-tau181P, or the mixed Ab1-42/
Ab40 ratio. Notwithstanding the fact that in this study
values for P-tau181P were lower, albeit not significant-
ly, in the DLB group compared to AD, differences
could be explained by the sample size, patients
enrolled in the study and/or the homogeneity of the
study group. These results will have to be confirmed
in larger studies.
A number of sandwich immunoassays that target
different phosphorylated epitopes of tau, including
Thr181 and Thr231, Thr231 and Ser235, Ser199,
Thr231, Thr181, and Ser396, and Ser404 have been
developed (20). Consistently increased levels of P-tau
in CSF from patients with AD have been found using
these assays (3). In a study directly comparing the
diagnostic performance of P-tau181P, P-tau199, and P-
tau231 in the same sets of patients, all three assays
performed equally well in the discrimination of AD
patients from non-demented subjects. Only minor dif-
ferences were found when group separation was
maximized between AD and FTD using P-tau231 and
between AD and DLB using P-tau181P controls (21).
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Furthermore, there was no difference in the prediction
of cognitive decline using each of the P-tau epitopes
in patients with mild cognitive impairment (22). The
present study confirms findings published in previous
reports that quantification of P-tau could be a useful
tool for differential diagnosis of neurodegenerative
disorders (5, 21, 23).
Numerous published reports have already men-
tioned the need for a multiparametric approach in the
domain of AD diagnosis. As in other areas of medi-
cine, CSF markers for AD may not be used in isola-
tion, but can provide added value to the information
obtained from clinical examination, brain-imaging
techniques (e.g., single photon emission CT and MRI),
and routine CSF biochemical analysis. It has already
been concluded that T-tau, Ab42, and P-tau181P, when
used as adjuncts to clinical diagnosis, have the poten-
tial to help differentiate AD from some difficult differ-
ential diagnoses (e.g., normal aging, depressive
pseudo-dementia, Parkinson’s disease, progressive
supranuclear palsy, and alcoholic dementia) (24) and
amyotrophic lateral sclerosis (25). The present study
confirms that better diagnostic performance com-
pared to single-parameter analysis can be obtained
for the discrimination of CS and AD using T-tau and
Ab1-42 (15). The P-tau181P/T-tau ratio can discriminate
patients with Creutzfeldt-Jakob disease from those
with other neurological disorders, including AD and
FTD (26, 27). Similar cutoff values were published for
discrimination of AD patients from controls by Lewc-
zuk et al. (28). Higher diagnostic accuracy was report-
ed for the combination of low CSF Ab1-42 and high
P-tau181P in differentiating early-onset AD from FTD (6)
and for differentiation of AD and healthy controls (29).
Identical results with respect to Ab1-42 and T-tau for
comparison between CS, AD, and DLB have been
published recently (30).
Individual markers have been demonstrated to be
of potential clinical use in the identification of early
AD. Further improvement will likely be achieved by
the creation of a complex model that includes several
biomarkers to adequately describe this phenomenon.
Published results on the diagnostic capacity of CSF
markers come from studies of clinically diagnosed
patients. This means that the diagnostic performance
of CSF markers cannot be higher than the accuracy of
the clinical diagnostic criteria used. Owing to this
diagnostic uncertainty and the heterogeneity of the
disease process, it may well be beneficial to select,
validate, and implement an algorithm that is based on
a combination of biomarkers to reduce the overlap
between different diagnostic groups.
The data available at present must be used with
caution when building ‘‘optimistic’’ models or algo-
rithms to estimate the performance in terms of clinical
accuracy. The clinical accuracy levels in the present
paper are mentioned as tentative estimates and not
as a final conclusion for a particular application. The
model should be validated and confirmed using a
larger number of samples.
A limitation of the present study is, of course, the
small cohort with the risk of selection bias and insuf-
ficient power to draw firm conclusions. The concen-
tration and cutoff values provided can be used for
guidance. However, given the center effect observed,
laboratories using this marker in a clinical setting
should first establish local reference ranges.
In conclusion, these data show that the INNOTEST
PHOSPHO-TAU(181P) is a robust and reliable assay that
can potentially be used in a diagnostic context. It will
be important to accumulate data from longitudinal
studies to interpret results of the biomarkers together
with imaging and neuropsychological markers.
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